Comparison · NCT02081963-sae
Nebulized Amikacin vs Nebulized Normal Saline: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nebulized Amikacin vs Nebulized Normal Saline: serious adverse events. Trial comparisons, record NCT02081963-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02081963-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.038 | 0.013 | 0.106 | wilson | |
| Risk in group 2 | 0.0137 | 0.00242 | 0.0736 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0243 | -0.0406 | 0.093 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.77 | 0.295 | 26.1 | log | |
| Odds ratio, group 1 over group 2 | 2.84 | 0.289 | 28 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nebulized Amikacin than on Nebulized Normal Saline | 41.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nebulized Amikacin | Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.~Amikacin: Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment. | 3 | 79 | EG000 |
| Group 2 | Nebulized Normal Saline | Participants received nebulized normal saline BID for 14 days in combination with standard treatment.~Normal saline: Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment. | 1 | 73 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
- NCT number
- NCT02081963
- Phases
- PHASE4
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- Amikacin, Normal saline
- Lead sponsor
- Qilu Hospital of Shandong University
- Results first posted
- 2019-04-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02081963?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02081963-sae